CL2025002925A1 - Compuestos derivados de pirido[4,3–d]pirimidina y uso para tratar cáncer. - Google Patents

Compuestos derivados de pirido[4,3–d]pirimidina y uso para tratar cáncer.

Info

Publication number
CL2025002925A1
CL2025002925A1 CL2025002925A CL2025002925A CL2025002925A1 CL 2025002925 A1 CL2025002925 A1 CL 2025002925A1 CL 2025002925 A CL2025002925 A CL 2025002925A CL 2025002925 A CL2025002925 A CL 2025002925A CL 2025002925 A1 CL2025002925 A1 CL 2025002925A1
Authority
CL
Chile
Prior art keywords
pyridino
treating cancer
pyrimidine derivatives
compounds
processes
Prior art date
Application number
CL2025002925A
Other languages
English (en)
Inventor
Cole Deforest Jacob
Nagata Asako
Paul Planken Simon
Elyse Spangler Jillian
Channing Sutton Scott
Joseph Burke Benjamin
Burtea Alexander
Maria Wisniewska Hanna
Yang Shouliang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CL2025002925A1 publication Critical patent/CL2025002925A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos de Fórmula (I)–(III) y sales farmacéuticamente aceptables de los mismos para usar en medicina; a composiciones que los contienen; a procesos para su preparación; y a intermediarios usados en dichos procesos. Los compuestos la presente invención pueden ser útiles en el tratamiento, la prevención, la supresión y la mejora de enfermedades, trastornos y afecciones tales como el cáncer.
CL2025002925A 2023-04-05 2025-09-26 Compuestos derivados de pirido[4,3–d]pirimidina y uso para tratar cáncer. CL2025002925A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202363494346P 2023-04-05 2023-04-05
US202363507621P 2023-06-12 2023-06-12
US202363540044P 2023-09-22 2023-09-22
US202363598907P 2023-11-14 2023-11-14
US202463550564P 2024-02-06 2024-02-06
US202463568399P 2024-03-21 2024-03-21

Publications (1)

Publication Number Publication Date
CL2025002925A1 true CL2025002925A1 (es) 2026-01-23

Family

ID=90720860

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025002925A CL2025002925A1 (es) 2023-04-05 2025-09-26 Compuestos derivados de pirido[4,3–d]pirimidina y uso para tratar cáncer.

Country Status (14)

Country Link
US (2) US20240336631A1 (es)
EP (1) EP4688788A1 (es)
KR (1) KR20250165440A (es)
CN (1) CN121079303A (es)
AU (1) AU2024253142A1 (es)
CL (1) CL2025002925A1 (es)
CO (1) CO2025013480A2 (es)
CR (1) CR20250413A (es)
DO (1) DOP2025000250A (es)
IL (1) IL323521A (es)
MX (1) MX2025011899A (es)
PE (1) PE20252775A1 (es)
TW (1) TW202504615A (es)
WO (1) WO2024209339A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA129778C2 (uk) 2019-10-28 2025-07-30 Мерк Шарп Енд Доум Елелсі Низькомолекулярні інгібітори g12c-мутантного kras
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026035947A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026078529A1 (en) * 2024-10-09 2026-04-16 Pfizer Inc. Solid and deuterated forms of pyrido[4,3-d]pyrimidine compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
PT2594590E (pt) 2007-12-14 2015-01-14 Bristol Myers Squibb Co Moléculas de ligação ao recetor humano ox40
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
CN104185477B (zh) 2011-11-17 2017-05-24 辉瑞公司 细胞毒性肽及其抗体‑药物缀合物
WO2016001810A1 (en) 2014-07-01 2016-01-07 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
TWI703159B (zh) 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
PT3440076T (pt) 2016-04-07 2022-07-29 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas úteis como modeladores de proteína
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
EP3541219B1 (en) 2016-11-16 2024-01-24 Wink Robotics Eyelid covering and stabilization for automatic eyelash extension
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
MY201312A (en) 2017-06-02 2024-02-16 Pfizer Antibodies specific for flt3 and their uses
JP2020530838A (ja) 2017-08-04 2020-10-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
BR112023024906A2 (pt) * 2021-05-28 2024-02-15 Redx Pharma Plc Compostos
US20250034166A1 (en) * 2021-09-27 2025-01-30 Jacobio Pharmaceuticals Co., Ltd. Polycyclic fused ring derivatives and use thereof
AU2023302139A1 (en) * 2022-07-05 2024-12-19 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
CN119790058A (zh) 2022-07-09 2025-04-08 荣山医药股份有限公司 用于治疗疾病的稠合环kras抑制剂
IL318647A (en) 2022-08-05 2025-03-01 Kumquat Biosciences Inc Heterocyclic compounds and their uses
WO2024032704A1 (en) 2022-08-11 2024-02-15 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2024041573A1 (en) 2022-08-25 2024-02-29 Zai Lab (Shanghai) Co., Ltd. Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof

Also Published As

Publication number Publication date
WO2024209339A1 (en) 2024-10-10
US12281127B2 (en) 2025-04-22
KR20250165440A (ko) 2025-11-25
PE20252775A1 (es) 2025-12-22
US20250034173A1 (en) 2025-01-30
IL323521A (en) 2025-11-01
MX2025011899A (es) 2025-11-03
CO2025013480A2 (es) 2025-10-09
DOP2025000250A (es) 2025-11-30
EP4688788A1 (en) 2026-02-11
TW202504615A (zh) 2025-02-01
CR20250413A (es) 2025-11-06
AU2024253142A1 (en) 2025-10-16
CN121079303A (zh) 2025-12-05
US20240336631A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
CL2025002925A1 (es) Compuestos derivados de pirido[4,3–d]pirimidina y uso para tratar cáncer.
DOP2024000275A (es) Compuestos de pirido[4,3-d]pirimidina
CL2023001461A1 (es) Inhibidores de prmt5 novedosos
CO2022015054A2 (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
AR127470A1 (es) Inhibidores de lrrk2
AR129003A1 (es) Compuestos heterocíclicos antivirales
UY40587A (es) Inhibidores del inflamasoma nlrp3
DOP2024000239A (es) Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas
CO2025003099A2 (es) Compuestos para el tratamiento del cáncer
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
CL2025000120A1 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b.
MX2023011377A (es) Derivados de ciclobutilo 1,3-sustituidos y sus usos.
MX2024012967A (es) Derivados de piridina para el tratamiento de los trastornos psiquiatricos
CL2025001109A1 (es) Compuestos derivados de pirazina-carboxamida.
CO2024015686A2 (es) Compuestos heteroaromáticos bicíclicos condensados y su uso en el tratamiento del cáncer
EA202192111A1 (ru) Новые тритерпеновые производные в качестве ингибиторов вич
AR134577A1 (es) Compuestos de bifenilo y fenilpiridina
MX2024013841A (es) Derivados de pirazina y usos de estos
MX2024013840A (es) Derivados de pirazina y usos de los mismos
MX2025009443A (es) Derivados de compuestos espiro sustituidos y su uso farmaceutico
AR134411A1 (es) Compuestos de uracilo
AR132880A1 (es) Derivados de heteroaril como inhibidores de ddr
CL2025001386A1 (es) Compuestos derivados de hexahidropirano[3',4':4,5]pirrolo[2,3-d]pirimidina y uso para tratar cáncer.
AR132628A1 (es) Compuestos derivados de feniloxazolona sustituida